Tags

Type your tag names separated by a space and hit enter

Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.
J Cardiovasc Pharmacol. 2020 Jun; 75(6):526-529.JC

Abstract

Coronavirus disease-2019 (COVID-19) has emerged as a pandemic affecting millions of adults. Severe acute respiratory syndrome coronavirus-2019 (SARS-CoV-2), the causative virus of COVID-19, infects host cells through angiotensin-converting enzyme 2 (ACE2). Preclinical models suggest that ACE2 upregulation confers protective effects in acute lung injury. In addition, renin-angiotensin aldosterone system inhibitors reduce adverse atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease outcomes, but may increase ACE2 levels. We review current knowledge of the role of ACE2 in cardiovascular physiology and SARS-CoV-2 virology, as well as clinical data to inform the management of patients with or at risk for COVID-19 who require renin-angiotensin-aldosterone system inhibitor therapy.

Links

PMC Free PDF

Authors+Show Affiliations

Buckley LF
Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA.
Cheng JWM
Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA. Department of Pharmacy Practice, MCPHS University, Boston, MA; and.
Desai A
Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.

MeSH

Angiotensin Receptor AntagonistsAngiotensin-Converting Enzyme 2Angiotensin-Converting Enzyme InhibitorsAnimalsBetacoronavirusCOVID-19Cardiovascular DiseasesCardiovascular Physiological PhenomenaCoronavirus InfectionsHumansMineralocorticoid Receptor AntagonistsPandemicsPeptidyl-Dipeptidase APneumonia, ViralRenin-Angiotensin SystemSARS-CoV-2

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32301766

Citation

Buckley, Leo F., et al. "Cardiovascular Pharmacology in the Time of COVID-19: a Focus On Angiotensin-Converting Enzyme 2." Journal of Cardiovascular Pharmacology, vol. 75, no. 6, 2020, pp. 526-529.
Buckley LF, Cheng JWM, Desai A. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2. J Cardiovasc Pharmacol. 2020;75(6):526-529.
Buckley, L. F., Cheng, J. W. M., & Desai, A. (2020). Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2. Journal of Cardiovascular Pharmacology, 75(6), 526-529. https://doi.org/10.1097/FJC.0000000000000840
Buckley LF, Cheng JWM, Desai A. Cardiovascular Pharmacology in the Time of COVID-19: a Focus On Angiotensin-Converting Enzyme 2. J Cardiovasc Pharmacol. 2020;75(6):526-529. PubMed PMID: 32301766.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2. AU - Buckley,Leo F, AU - Cheng,Judy W M, AU - Desai,Akshay, PY - 2020/4/18/pubmed PY - 2020/6/10/medline PY - 2020/4/18/entrez SP - 526 EP - 529 JF - Journal of cardiovascular pharmacology JO - J Cardiovasc Pharmacol VL - 75 IS - 6 N2 - Coronavirus disease-2019 (COVID-19) has emerged as a pandemic affecting millions of adults. Severe acute respiratory syndrome coronavirus-2019 (SARS-CoV-2), the causative virus of COVID-19, infects host cells through angiotensin-converting enzyme 2 (ACE2). Preclinical models suggest that ACE2 upregulation confers protective effects in acute lung injury. In addition, renin-angiotensin aldosterone system inhibitors reduce adverse atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease outcomes, but may increase ACE2 levels. We review current knowledge of the role of ACE2 in cardiovascular physiology and SARS-CoV-2 virology, as well as clinical data to inform the management of patients with or at risk for COVID-19 who require renin-angiotensin-aldosterone system inhibitor therapy. SN - 1533-4023 UR - https://www.unboundmedicine.com/medline/citation/32301766/Cardiovascular_Pharmacology_in_the_Time_of_COVID_19:_A_Focus_on_Angiotensin_Converting_Enzyme_2_ DB - PRIME DP - Unbound Medicine ER -